Alison M. Friedmann

Hematology | Oncology
55 Fruit St
Boston, MA 02114

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Clofarabine for relapsed/refractory LCH and non-LC histiocytosis.

Clofarabine for relapsed/refractory LCH and non-LC histiocytosis.

Journal: Blood advances
Published: February 11, 2026

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Journal: Blood advances
Published: February 11, 2026

Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy.

Characterization of Clinical Outcomes for Patients with Relapsed High-Risk Neuroblastoma After Autologous Stem Cell Transplant and External Beam Radiotherapy.

Journal: Cancers
Published: January 23, 2026

Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.

Dose-dense chemotherapy enables elimination of RT for majority of low-risk pediatric Hodgkin lymphoma: PHC study HOD08.

Journal: Blood
Published: April 11, 2025

Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08.

Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08.

Journal: Blood
Published: April 11, 2025

Adult onset wilms tumor.

Adult onset wilms tumor.

Journal: Radiology case reports
Published: December 09, 2024

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: January 09, 2024

A 6-Week-Old Boy With Irritability and Abdominal Distension.

A 6-Week-Old Boy With Irritability and Abdominal Distension.

Journal: Pediatrics
Published: January 04, 2024

Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90.

Disease site number was not prognostic in a low-risk Hodgkin lymphoma combined modality trial: revisiting PHC HOD90.

Journal: Blood advances
Published: June 12, 2023

Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.

Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.

Journal: Pediatric blood & cancer
Published: March 01, 2023

Secondary histiocytic sarcoma with BRAFV600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy.

Secondary histiocytic sarcoma with BRAFV600E mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapy.

Journal: Pediatric blood & cancer
Published: April 26, 2021

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 07, 2021
Showing 1-12 of 43

Last Updated: 09/26/2026